Canaccord maintained a buy rating and $336 price target on Madrigal Pharmaceuticals, telling investors in a research note that the CEO change creates a strong buying opportunity. The firm, which remains bullish on shares, believes the leadership transition makes sense as new CEO Bill Sibold has a strong background in launching drugs and overall commercial activities.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MDGL:
- Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer
- Madrigal Pharmaceuticals appoints Bill Sibold as CEO
- Paulson buys Madrigal, exits Bally’s in Q2
- Biotech Alert: Searches spiking for these stocks today
- Madrigal Pharmaceuticals price target lowered to $285 from $350 at Oppenheimer